Skip to main content
Journal cover image

Cellular and molecular targeting for nanotherapeutics in transplantation tolerance.

Publication ,  Journal Article
Hlavaty, KA; Luo, X; Shea, LD; Miller, SD
Published in: Clin Immunol
September 2015

The induction of donor-specific tolerance to transplanted cells and organs, while preserving immune function as a whole, remains a highly sought after and elusive strategy for overcoming transplant rejection. Tolerance necessitates modulating a diverse array of cell types that recognize and respond to alloantigens, including antigen presenting cells and T lymphocytes. Nanotherapeutic strategies that employ cellular and biomaterial engineering represent an emerging technology geared towards the goal of inducing transplant tolerance. Nanocarriers offer a platform for delivering antigens of interest to specific cell types in order to achieve tolerogenic antigen presentation. Furthermore, the technologies also provide an opportunity for local immunomodulation at the graft site. Nanocarriers delivering a combination of antigens and immunomodulating agents, such as rapamycin, provide a unique technology platform with the potential to enhance outcomes for the induction of transplant tolerance.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Immunol

DOI

EISSN

1521-7035

Publication Date

September 2015

Volume

160

Issue

1

Start / End Page

14 / 23

Location

United States

Related Subject Headings

  • Transplantation Tolerance
  • Tacrolimus
  • Sirolimus
  • Nanomedicine
  • Molecular Targeted Therapy
  • Immunosuppressive Agents
  • Immunomodulation
  • Immunology
  • Humans
  • Graft Survival
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hlavaty, K. A., Luo, X., Shea, L. D., & Miller, S. D. (2015). Cellular and molecular targeting for nanotherapeutics in transplantation tolerance. Clin Immunol, 160(1), 14–23. https://doi.org/10.1016/j.clim.2015.03.013
Hlavaty, Kelan A., Xunrong Luo, Lonnie D. Shea, and Stephen D. Miller. “Cellular and molecular targeting for nanotherapeutics in transplantation tolerance.Clin Immunol 160, no. 1 (September 2015): 14–23. https://doi.org/10.1016/j.clim.2015.03.013.
Hlavaty KA, Luo X, Shea LD, Miller SD. Cellular and molecular targeting for nanotherapeutics in transplantation tolerance. Clin Immunol. 2015 Sep;160(1):14–23.
Hlavaty, Kelan A., et al. “Cellular and molecular targeting for nanotherapeutics in transplantation tolerance.Clin Immunol, vol. 160, no. 1, Sept. 2015, pp. 14–23. Pubmed, doi:10.1016/j.clim.2015.03.013.
Hlavaty KA, Luo X, Shea LD, Miller SD. Cellular and molecular targeting for nanotherapeutics in transplantation tolerance. Clin Immunol. 2015 Sep;160(1):14–23.
Journal cover image

Published In

Clin Immunol

DOI

EISSN

1521-7035

Publication Date

September 2015

Volume

160

Issue

1

Start / End Page

14 / 23

Location

United States

Related Subject Headings

  • Transplantation Tolerance
  • Tacrolimus
  • Sirolimus
  • Nanomedicine
  • Molecular Targeted Therapy
  • Immunosuppressive Agents
  • Immunomodulation
  • Immunology
  • Humans
  • Graft Survival